Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

High-bar response endpoints, including vIGA-AD scores of clear or almost clear skin and EASI 75, a 75% improvement in disease severity from baseline, have become the standard efficacy benchmark the 

In the pooled phase 3 ADORING 1 and ADORING 2 population, most enrolled patients had significant baseline disease, with many meeting typical criteria for systemic therapy candidacy, yet achieved these high-bar responses with a once-daily nonsteroidal topical cream by Week 8.

Topical corticosteroids remain the mainstay of atopic dermatitis treatment for many pediatric patients, offering effective short-term control but posing limitations for the long-term, body-wide management this chronic disease often requires.

 A single nonsteroidal option applicable across multiple body surface areas, including the face and skin folds, can simplify a treatment regimen that might otherwise require several separate products.

Tapinarof cream 1% (VTAMA) is also FDA approved for plaque psoriasis in adults, positioning it within a broader class of nonsteroidal options intended to reduce reliance on topical steroids across chronic inflammatory skin diseases.

 Despite this expanding approval down to age 2, pediatric atopic dermatitis remains an area of substantial unmet need, particularly for infants and toddlers younger than the currently studied population.

Linda Stein Gold, MD, director of dermatology clinical research, Henry Ford Health, Detroit, Michigan, discusses the clinical implications of the ADORING age-stratified findings and where treatment gaps remain in the youngest patients with atopic dermatitis. The following Q&A highlights her views discussed in the interview:

HCPLive: What do endpoints like EASI 75 and vIGA-AD tell us about treatment response?

 It's interesting because I've been doing clinical trials my entire career, and when I first started, our bars for treatment success were very low. Now the FDA mandates we have these really high bars. Clear or almost clear means the skin is completely clear all over the body, or there might be a little bit of pink skin. That's really impressive. EASI 75 is a 75% improvement from where they started. What we have to realize is the patients who came into this study had significant disease. On average, they were candidates for systemic therapy. So the fact we can use a nonsteroidal topical cream once a day and see these high benchmarks as early as 8 weeks is really important.

HCPLive: How might these findings influence how clinicians manage atopic dermatitis across age groups?

 We have needed better treatment options, especially for our youngest atopic patients. We've turned to topical steroids as the mainstay of therapy, and they're a good short-term solution, but they're not a long-term solution, and this is a long-term problem. We need better options that are not steroids and can be used on multiple body surface areas. This helps simplify the treatment regimen. Imagine instead of giving patients four or five things to do, we can give them one thing to do that they can use on all body surface areas, including the face, the skin folds, the thicker areas, the hands, and they can use it to get the disease under control and keep it under control.

HCPLive: What unmet needs remain in pediatric atopic dermatitis?

 The good news is we have treatment options that are great and nonsteroidal that go down to age 2. But I'd love to see these medications like tapinarof being studied in even younger populations, a 3-month-old or a 4-month-old. So I think we have an unmet need for our even younger patients.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Disclosures for Stein Gold include AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Organon Health, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB

Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):487-495. doi:

Organon. New analysis of phase 3 pooled data for Organon's VTAMA (tapinarof) cream, 1%, demonstrates early, consistent improvements in atopic dermatitis patients across pediatric age groups and in adults. News release. Organon. Published July 24, 2026. Accessed August 5, 2026. 

https://www.organon.com/news/new-analysis-of-phase-3-pooled-data-for-organons-vtama-tapinarof-cream-1-demonstrates-early-consistent-improvements-in-atopic-dermatitis-patients-across-pediatric-age-groups-and-in/

Organon. Organon to present new analysis on VTAMA (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting. News release. Organon. Published March 27, 2026. Accessed August 5, 2026. 

https://www.organon.com/news/organon-debuts-new-analysis-of-vtama-tapinarof-cream-1-phase-3-pooled-data-demonstrating-early-and-consistent-skin-clearance-and-itch-improvement-in-atopic-dermatitis-patients-down-to-2-year/

Articles

High-bar FDA endpoints for atopic dermatitis trials now emphasize vIGA-AD clear/almost clear and EASI 75. In pooled phase 3 ADORING 1/2 data, patients with substantial baseline disease—often meeting systemic-therapy candidacy—achieved these benchmarks by Week 8 with once-daily tapinarof cream 1%, a nonsteroidal topical. Broader, steroid-sparing use across sensitive and intertriginous areas may simplify multi-product regimens. Despite approvals down to age 2, major evidence gaps persist for infants and younger toddlers.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Q&A: Tapinarof Data Highlight Unmet Pediatric Needs in Atopic Dermatitis

 formalize 3 second-line treatment options: remibrutinib (Rhapsido), omalizumab (Xolair), and dupilumab (Dupixent).

Adam Friedman, MD, FAAD, professor and chair of dermatology, residency program director, Department of Dermatology, George Washington University School of Medicine and Health Sciences, discussed the update at the 2026 Dermatology Education Foundation (DEF) DERM2026 conference in Las Vegas.

Adam Friedman, MD, FAAD, of George Washington University School of Medicine and Health Sciences, discusses how chronic spontaneous urticaria (CSU) management guidance has evolved. He spoke with HCPLive after presenting at DERM2026 in Las Vegas.  Read the full coverage: https://www.hcplive.com/view/navigating-second-line-treatments-in-2026-csu-guidelines-with-adam-friedman-md 

Adam Friedman, MD, on CSU Treatment Updates | HCPLive

The guidelines also reinforce rapid escalation of second-generation, non-sedating H1 antihistamines, moving from standard to quadruple dosing within 3 to 4 weeks of diagnosis. Friedman noted European guidance has moved faster on this timeline than the 2014 US Joint Task Force parameters. These updates build on 

prior HCPLive coverage of the same guideline revision

"We've got 3 on-label options for the management of a disease that affects 1% of the global population that is uniquely burdensome because it comes out of nowhere, no matter what you're doing, and there's no underlying cause based on the definition. It's more about which one makes the most sense for your patient," Friedman said.

Omalizumab carries roughly a decade of real-world and trial experience, but the guidelines list all 3 second-line options without ranking preference. Friedman said the expanded menu lets clinicians match therapy to patient preference, injection versus oral dosing, comorbidity profile, and prior response.

Third-line options remain cyclosporine and off-label immunosuppressants, including mycophenolate mofetil, azathioprine, and methotrexate. Friedman cited a George Washington University resident survey showing many trainees feel comfortable managing CSU but are unaware the guidelines exist, pointing to a gap in guideline dissemination rather than clinical readiness.

Dermatology Education Foundation. DERM2026 agenda. https://dermnppa.org/derm2026-agenda/. Accessed August 5, 2026.

HCPLive. Updated guidelines and the current CSU treatment landscape. 

https://www.hcplive.com/view/updated-guidelines-and-the-current-csu-treatment-landscape

. Published July 8, 2026. Accessed August 5, 2026.

Videos

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Navigating Second-Line Treatments in 2026 CSU Guidelines, With Adam Friedman, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

has approved oveporexton (Orzeyful) tablets for 

in adults, the first medicine to directly target orexin signaling loss and address the disorder as a complete condition.¹

Existing narcolepsy type 1 therapies, including stimulants and sedatives, manage individual symptoms without addressing the underlying orexin deficiency driving the disorder. Oveporexton is the first agent to activate the OX2R receptor directly, restoring the signal lost when orexin-producing neurons are destroyed. The approval was granted to Takeda Pharmaceuticals America, Inc, following Breakthrough Therapy Designation and Priority Review.¹

“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it,” said Tiffany R. Farchione, MD, director of the division of psychiatry at the FDA Center for Drug Evaluation and Research, in a statement. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.”¹

Oveporexton Efficacy in FirstLight and RadiantLight

The approval rests on 2 randomized, double-blind, placebo-controlled 12-week trials enrolling 273 adults with narcolepsy type 1, FirstLight (NCT06470828, n = 168) and RadiantLight (NCT06505031, n = 105).2 FirstLight, conducted across 19 countries, included high-dose, low-dose, and placebo arms, while RadiantLight tested only the high-dose regimen against placebo.³ Both trials assessed oveporexton dosed at 1 mg or 2 mg twice daily, using change in Maintenance Wakefulness Test score as the primary endpoint.³

Across both studies, patients receiving oveporexton 2 mg showed significant improvements in their ability to stay awake during the day compared with placebo (

 <.001).¹ Patients also reported substantially less daytime sleepiness and a significant reduction in cataplexy episodes.¹ Data presented at the 2025 World Sleep Congress showed both trials met all primary and secondary endpoints, with improvements reaching near-normal ranges by week 12.²

Oveporexton Safety and Secondary Endpoints

Beyond wakefulness, oveporexton produced meaningful improvement across the full spectrum of narcolepsy type 1 symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep.¹

What is oveporexton (Orzeyful) approved for?

Oveporexton is approved for narcolepsy type 1 in adults, the first medicine addressing the disorder as a complete condition rather than one isolated symptom.


It is an oral orexin receptor 2-selective agonist that directly activates the receptor normally stimulated by orexin, restoring the signaling lost when orexin-producing neurons are destroyed in NT1.

What did the FirstLight and RadiantLight trials show?


Both phase 3 trials met their primary and secondary endpoints, with oveporexton 2 mg producing significant improvement in daytime wakefulness and reductions in cataplexy versus placebo (both 

The most common adverse events were insomnia, increased urinary frequency, urgency to urinate, and increased saliva production, with a low rate of discontinuation due to side effects.¹ Oveporexton should not be co-administered with strong CYP3A inhibitors, and safety and effectiveness have not been established in patients under 18 years.¹ The drug has been recommended for scheduling under the Controlled Substances Act and will require a DEA scheduling decision before marketing begins.¹

"Our research has shown that the loss of orexin is the cause of narcolepsy type 1, which results in symptoms like excessive daytime sleepiness and cataplexy," said FirstLight investigator Emmanuel Mignot, MD, PhD, Craig Reynolds Professor of Sleep Medicine at Stanford University, in a statement.³

Orzeyful was previously approved in China in July 2026 as the first orexin agonist and only approved medicine for NT1, and Takeda has additional orexin agonists in development for narcolepsy type 2 and idiopathic hypersomnia.⁴ Marketing in the US remains contingent on the DEA's final scheduling decision under the Controlled Substances Act.¹

FDA Approves First Drug To Treat The Full Range Of Narcolepsy Type 1 Symptoms. U.S. Food and Drug Administration. Published August 5, 2026. Accessed August 5, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms

Ciccone I. FDA accepts new drug application for orexin agonist oveporexton in narcolepsy type 1, grants priority review. NeurologyLive. Published February 11, 2026. Accessed August 5, 2026. 

https://www.neurologylive.com/view/fda-accepts-nda-orexin-agonist-oveporexton-nt1-grants-priority-review

Takeda Presents Orexin Data From Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025. Takeda. Published September 8, 2025. Accessed August 5, 2026. 

https://www.takeda.com/newsroom/newsreleases/2025/takeda-orexin-data-oveporexton-phase-3-narcolepsy-world-sleep-2025/

Takeda's ORZEYFUL (Oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1. Takeda. Published July 22, 2026. Accessed August 5, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-china-narcolepsy/

FDA approved oveporexton (Orzeyful) for adult narcolepsy type 1, representing the first therapy to directly address orexin signaling loss via OX2R agonism. Approval was supported by two 12-week, randomized, double-blind, placebo-controlled phase 3 trials (FirstLight, RadiantLight; n=273) using change in Maintenance Wakefulness Test as the primary endpoint. High-dose 2 mg twice daily improved wakefulness, reduced daytime sleepiness, and decreased cataplexy, with additional benefits across other NT1 symptoms.  

FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.

FDA News

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1

A single dose of oral encapsulated fecal microbiota transplantation (FMT) increased the peanut reactivity threshold in 6 of 15 adults with 

(40%) in a phase 1 open-label trial, with the effect sustained at 4 months and, in a subset, out to 12 months.¹

“This landmark study was the first to demonstrate that a microbiome-based therapy may improve food allergy in people while also revealing how gut bacteria, their metabolites, and the immune system work together to influence treatment response,” said Rima Rachid, MD, director of the Food Allergy Program and the Allergen Immunotherapy Program, at Boston Children’s Hospital, in a statement.

Peanut oral immunotherapy with AR101 (Palforzia) was the only FDA-approved disease-modifying option for peanut allergy, but the manufacturer discontinued the product, leaving no approved peanut oral immunotherapy (OIT) on the market.

 Off-label desensitization protocols still require close to 6 months of daily dosing to reach a 300 mg tolerance threshold and carry high rates of allergic reactions, taste aversion, and nonadherence.

 Prior mouse work from this group showed FMT from healthy donors, but not from patients with food allergy, protects against anaphylaxis in a food allergy–prone model, motivating this first-in-human application of FMT to peanut allergy.

Peanut Reactivity Threshold Outcomes in the FMT Trial

Investigators enrolled 15 adults aged 18 to 40 years, all reactive to ≤ 100 mg of peanut protein on double-blind placebo-controlled food challenge (DBPCFC) at baseline.

 In part A, 10 participants received a single dose of 36 encapsulated FMT capsules from 1 of 3 nonatopic donors without antibiotic pretreatment, and 3 of 10 (30%; 95% CI, 6.7-65.3%) achieved secondary efficacy, defined as an increased reactivity threshold to 300 mg or 600 mg of peanut at 1 and 4 months.

In part B, 5 additional participants received FMT after a 4-day pretreatment regimen of oral vancomycin, neomycin, and metronidazole, and 3 of 5 (60%; 95% CI, 14.7-94.7%) achieved secondary efficacy. FMT was safe across all 15 participants, with only 3 grade 1 and 2 grade 2 adverse events, all resolving within 12 to 48 hours and nonconsistent with immediate hypersensitivity. Five of 6 responders were male compared with 2 of 9 nonresponders (

 =.041), though the cohort was too small to draw firm conclusions on sex as a predictor.

Microbiome Mechanism and Bile Acid Metabolism in Responders

Responders showed no change in total circulating Treg cell percentages but had significant increases in tolerogenic RORγt+ Treg cells at 1 month (

 =.0052) after FMT, sustained at 1 year (

 =.0004) among those completing the exit visit. Responders also had a decrease in circulating IL-13-expressing CD4 T cells at 1 month (

Human stool 16S and metagenomic profiles did not distinguish responders from nonresponders. Transfer of post-FMT responder stool into germ-free Il4raF709 mice protected against anaphylaxis across 3 sensitization models, while nonresponder stool did not. Protection tracked with Bacteroides colonization, gut RORγt+ Treg cell expansion, and suppression of IL-13+ TFH13 cells and intestinal mast cell expansion.

Serum cholate rose in responders after FMT but not in nonresponders. Deleting the bile salt hydrolase gene from Bacteroides ovatus eliminated both its protective effect against anaphylaxis and its ability to induce RORγt+ Treg cells in mice, implicating microbial bile acid metabolism as a driver of oral tolerance.

Investigators note the dose and frequency of FMT remain unoptimized, and the role of antibiotic pretreatment in maximizing response requires further study in larger, randomized, double-blind, placebo-controlled trials involving both sexes.¹

“Larger studies of fecal and microbiota transplantation are now essential to confirm these findings, identify the patients most likely to benefit, and discover beneficial bacteria that could be developed into targeted probiotic therapies for food allergy,” Rachid said.

Rachid R, Martinez-Blanco M, Kuziel GA, et al. Fecal microbiome transplant in food allergy in humans and mice identifies a role for bile acid metabolites in oral tolerance. 

How ‘good’ bacteria from fecal transplants reduce peanut allergy. EurekAlert! Published August 5, 2026. Accessed August 5, 2026. 

https://www.eurekalert.org/news-releases/1138079

Wood and Ross. Palforzia Discontinued, Ending the Only FDA-Approved Peanut OIT Option. HCPLive. Published July 31, 2026. Accessed August 5, 2026. 

https://www.hcplive.com/view/palforzia-discontinued-ending-only-fda-approved-peanut-oit

ClinicalTrials.gov. Fecal microbiota transplantation for food allergy. NCT02960074. 

https://clinicaltrials.gov/study/NCT02960074

A phase 1 open-label study tested single-dose oral encapsulated fecal microbiota transplantation in 15 adults with peanut allergy reactive to ≤100 mg on DBPCFC. With no approved peanut OIT after Palforzia discontinuation, this approach offers a potential alternative. Six participants (40%) increased their reactivity threshold to 300–600 mg, with responses persisting 4 months and, in some, 12 months; antibiotic pretreatment appeared to raise response rates. Clinical benefit correlated with expansion of tolerogenic RORγt+ Treg cells, reduced IL‑13–expressing CD4 subsets, and donor-derived microbial bile acid metabolism, supporting microbiome-driven oral tolerance.

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Fecal Microbiota Transplant Boosts Peanut Tolerance in Phase 1 Trial

Genevieve Gauthier, MSc, serves as a senior director and Real-World Evidence (RWE) Scientist for Inflammation and Immunology at Pfizer.

About 1 in 3 patients diagnosed with vitiligo did not go on to receive treatment, data suggest.

Among treated patients, therapy duration was short, often just two to four months per line of treatment.

Children and adolescents were more likely to receive topical-only treatment, while systemic options were more common in adults.

 remains a chronic condition with limited standardized treatment approaches, and new real-world data are shedding light on just how inconsistent care can be.

 Q&A interview, Genevieve Gauthier, MSc, highlighted findings from a recent 

 study examining treatment patterns among nearly 25,000 patients with vitiligo, including how often individuals go untreated after diagnosis and how long they typically stay on therapy once their treatment begins.

Gauthier also explores how treatment approaches differ across age groups, why visible lesions may carry a heightened psychosocial burden, and what these real-world patterns reveal about unmet needs in vitiligo care. The following Q&A highlights Gauthier’s responses to 

: One of the biggest findings in your study was that many patients with vitiligo did not receive treatment during follow-up. Why do you think so many patients are going untreated, and what does that say about the current state of vitiligo care?

 Our study described what’s happening rather than the reasons behind individual treatment decisions, so I can’t speak in detail to the “why.” What makes this finding particularly meaningful is the context: these were patients who had been diagnosed, who had entered the healthcare system, and in many cases were diagnosed by a dermatologist (46.4%), and still a substantial share didn’t go on to treatment.

Additionally, among patients who were treated, therapy duration was relatively short, a median of roughly two to four months for first and second lines of therapy, and treatment sequences varied substantially from patient to patient. In totality, those findings suggest that current treatment approaches may not, in some vitiligo patients, be meeting patients' needs over the long term.

: You also found that treatment duration was often fairly short. What do you think is contributing to patients stopping or switching therapies so quickly in real-world practice?

We were not able to determine the specific reasons why patients discontinued or switched therapies as this information was not available in the databases we used for this study. However, when considered alongside the high variability observed in treatment sequences, these findings may suggest that some patients with vitiligo face limited long-term treatment options and a lack of standardized, sustained approaches to care.

In real-world clinical practice, these patterns could be influenced by multiple factors, including heterogeneity in patient response, tolerability considerations, challenges with long-term adherence, and the overall complexity of managing a chronic condition like vitiligo. That being said, additional studies would be warranted to better understand what is driving treatment discontinuation and switch in vitiligo patients and inform future research and development of durable treatment strategies.

: The face was the most commonly affected area in your analysis. How important is it for clinicians to consider the emotional and quality-of-life impact of vitiligo, especially when visible areas are involved?

 While we didn’t measure quality-of-life in our study, there is a substantial body of literature showing that vitiligo carries a significant psychosocial burden impacting patients’ quality of life. Studies have also demonstrated that patients with facial lesions have a higher psychosocial burden vs. those without facial lesions.

To me the fact that most patients in our study had visible lesions on the face underscores the need for clinicians to take a more holistic approach to vitiligo care – an approach that goes beyond clinical measures and fully considers the broader patient experience

: Your study showed some differences in treatment patterns between children and adults. Were there any age-related trends that surprised you, and how should dermatologists think about treating younger patients with vitiligo?

Results from our study showed that children and adolescents were more likely than adults to receive topical treatments, while systemic treatments, including oral corticosteroids, were more common in adults. As a first line, topical-only treatment was used in roughly 90% of children and 80% of adolescents, versus about 60% of adults. These findings weren’t surprising as they are consistent with evidence supporting their use in pediatric patients.

: For dermatologists reading this study, what do you think is the most important takeaway about how vitiligo is currently being treated in the real world, and where do you still see the biggest unmet needs for patients?

 The most important takeaway to me is that there are still clear gaps in vitiligo care and significant room to improve outcomes and quality of life in patients living with vitiligo. Across nearly 25,000 patients, about one in three diagnosed patients didn’t go on to receive treatment; those who were treated tended to stay on therapy only a few months, and treatment sequences varied widely. Those patterns held across age groups and disease extent, and are in line with other recent real-world analyses, providing a coherent picture of how vitiligo is being managed in the US today.

Overall, these findings highlight a lack of standardized approaches, and that current treatment approaches may not, in some patients, fully address patients’ long-term needs. Insights like these could help inform future research and clinical practice and, ultimately, potentially contribute to improving outcomes for people living with vitiligo.

Disclosures: Gauthier reported employment with Pfizer during the conduct of the study.

Sheikh A, Rafique W, Ali E. FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology. Ann Med Surg (Lond). 2022 Aug 28;81:104499. 

Adiri R, Gauthier G, Hamzavi I, et al. Clinical Characteristics and Treatment Patterns in Patients With Vitiligo. JAMA Dermatol. 2026 Jul 1;162(7):720-725. 

Real-world US data from nearly 25,000 patients with vitiligo demonstrate substantial care gaps after diagnosis, despite frequent dermatology involvement. Approximately one-third received no treatment during follow-up, and those initiating therapy typically remained on first- or second-line regimens only two to four months, with highly variable sequencing. Facial involvement was common, reinforcing the likelihood of amplified psychosocial morbidity in visible disease. Age stratification showed pediatric patients predominantly managed with topical-only approaches, whereas adults more often received systemic therapies.

A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Real-World Data Reveal Gaps in Vitiligo Treatment, With Genevieve Gauthier, MSc

Matthew C. Breeggemann, MD is a nephrologist who cares for patients with kidney disease. He is medical director of UCSF's Kidney Stone Prevention Clinic, where he treats patients with a variety of kidney stone disorders in collaboration with the department of urology.

Matthew Breeggemann, MD, UCSF nephrologist, explains how CKD is diagnosed, monitored, and why new CKD therapies take years to reach patients.

How a Nephrologist Diagnoses and Manages Chronic Kidney Disease

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity

Daniela Ciciulla, APD, CEDC, MDiet, a PhD candidate at the University of Melbourne.

A study found children with and without food allergy screen positive for possible ARFID at similar rates, Daniela Ciciulla, APD, CEDC, says.

Q&A: 1 in 5 Children with Food Allergy Screen Positive for Possible ARFID

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The FDA approved a 12-hour OTC combination of guaifenesin, dextromethorphan, and naproxen for cold and influenza symptom relief.

Influenza

The HCPLive influenza page is a resource for medical news and expert insights on the flu. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for influenza, and more.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Approves Mucinex 12HR Cold & Fever Multi-Symptom for OTC Use

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Tomashefski discusses where AATD diagnoses go missed and why APPs are positioned to close the gap.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Closing the AATD Diagnostic Gap, With Sarah Tomashefski, MSN

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

3 Psychiatry Headlines You Missed in July 2026

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Q&A: How STOP-HS Povorcitinib Data Impact Hidradenitis Suppurativa

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA

Hepatology

5 Hepatology Headlines You Missed in July 2026

Podcasts

This episode covers the recently announced topline data from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials, as well as a study investigating online GLP-1 sales.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Latest News

Q&A: Tapinarof Data Highlight Unmet Pediatric Needs in Atopic Dermatitis

Navigating Second-Line Treatments in 2026 CSU Guidelines, With Adam Friedman, MD

FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1

Fecal Microbiota Transplant Boosts Peanut Tolerance in Phase 1 Trial

Real-World Data Reveal Gaps in Vitiligo Treatment, With Genevieve Gauthier, MSc